Relapse of thrombotic thrombocytopenic purpura: Is it a continuum of disease?

Monte Willis, Nicholas Bandarenko

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

The recurrence of thrombotic thrombocytopenic purpura (TTP) in 20 to 50% of patients who survive their initial episode, is not only a challenge to manage clinically, but brings to light our lack of understanding of the underlying pathophysiology. Recurrence may occur close to apparent hematologic remission or remotely, months later. Given that surveillance of TTP relies on surrogate measures such as hematologic recovery, normalization of serum lactate dehydrogenase (LDH) and resolution of clinical signs, it is plausible that some recurrences are actually a continuum of disease. Standardizing definitions for remission, exacerbation, and relapse are important for consistency of patient management and interpreting the medical literature. When TTP recurs, several adjuncts to therapeutic plasma exchange (TPE) have been used, including splenectomy, vincristine, and rituximab. Although it would seem intuitive that more severe disease would predict a greater likelihood of relapse, the degree of thrombocytopenia at presentation, the persistence of schistocytosis at discontinuation of TPE, the elevation of LDH, and the length of time to attain clinical remission are not reliable indicators of the clinical outcome of any individual TTP patient. Measurement of ADAMTS13 activity and its inhibitor offer new promise for prognostic and pathophysiologic significance; however, more extensive scientific investigation is needed.

Original languageEnglish (US)
Pages (from-to)700-708
Number of pages9
JournalSeminars in Thrombosis and Hemostasis
Volume31
Issue number6
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Thrombotic Thrombocytopenic Purpura
Recurrence
Plasma Exchange
L-Lactate Dehydrogenase
Vincristine
Splenectomy
Thrombocytopenia
Therapeutics
Serum

Keywords

  • Adjunct therapy
  • Prognostic factors
  • Relapse
  • Thrombotic thrombocytopenic purpura (TTP)

ASJC Scopus subject areas

  • Hematology

Cite this

Relapse of thrombotic thrombocytopenic purpura : Is it a continuum of disease? / Willis, Monte; Bandarenko, Nicholas.

In: Seminars in Thrombosis and Hemostasis, Vol. 31, No. 6, 01.12.2005, p. 700-708.

Research output: Contribution to journalReview article

@article{552139ad8a224d43a8d0e7367049bfa7,
title = "Relapse of thrombotic thrombocytopenic purpura: Is it a continuum of disease?",
abstract = "The recurrence of thrombotic thrombocytopenic purpura (TTP) in 20 to 50{\%} of patients who survive their initial episode, is not only a challenge to manage clinically, but brings to light our lack of understanding of the underlying pathophysiology. Recurrence may occur close to apparent hematologic remission or remotely, months later. Given that surveillance of TTP relies on surrogate measures such as hematologic recovery, normalization of serum lactate dehydrogenase (LDH) and resolution of clinical signs, it is plausible that some recurrences are actually a continuum of disease. Standardizing definitions for remission, exacerbation, and relapse are important for consistency of patient management and interpreting the medical literature. When TTP recurs, several adjuncts to therapeutic plasma exchange (TPE) have been used, including splenectomy, vincristine, and rituximab. Although it would seem intuitive that more severe disease would predict a greater likelihood of relapse, the degree of thrombocytopenia at presentation, the persistence of schistocytosis at discontinuation of TPE, the elevation of LDH, and the length of time to attain clinical remission are not reliable indicators of the clinical outcome of any individual TTP patient. Measurement of ADAMTS13 activity and its inhibitor offer new promise for prognostic and pathophysiologic significance; however, more extensive scientific investigation is needed.",
keywords = "Adjunct therapy, Prognostic factors, Relapse, Thrombotic thrombocytopenic purpura (TTP)",
author = "Monte Willis and Nicholas Bandarenko",
year = "2005",
month = "12",
day = "1",
doi = "10.1055/s-2005-925476",
language = "English (US)",
volume = "31",
pages = "700--708",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "6",

}

TY - JOUR

T1 - Relapse of thrombotic thrombocytopenic purpura

T2 - Is it a continuum of disease?

AU - Willis, Monte

AU - Bandarenko, Nicholas

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The recurrence of thrombotic thrombocytopenic purpura (TTP) in 20 to 50% of patients who survive their initial episode, is not only a challenge to manage clinically, but brings to light our lack of understanding of the underlying pathophysiology. Recurrence may occur close to apparent hematologic remission or remotely, months later. Given that surveillance of TTP relies on surrogate measures such as hematologic recovery, normalization of serum lactate dehydrogenase (LDH) and resolution of clinical signs, it is plausible that some recurrences are actually a continuum of disease. Standardizing definitions for remission, exacerbation, and relapse are important for consistency of patient management and interpreting the medical literature. When TTP recurs, several adjuncts to therapeutic plasma exchange (TPE) have been used, including splenectomy, vincristine, and rituximab. Although it would seem intuitive that more severe disease would predict a greater likelihood of relapse, the degree of thrombocytopenia at presentation, the persistence of schistocytosis at discontinuation of TPE, the elevation of LDH, and the length of time to attain clinical remission are not reliable indicators of the clinical outcome of any individual TTP patient. Measurement of ADAMTS13 activity and its inhibitor offer new promise for prognostic and pathophysiologic significance; however, more extensive scientific investigation is needed.

AB - The recurrence of thrombotic thrombocytopenic purpura (TTP) in 20 to 50% of patients who survive their initial episode, is not only a challenge to manage clinically, but brings to light our lack of understanding of the underlying pathophysiology. Recurrence may occur close to apparent hematologic remission or remotely, months later. Given that surveillance of TTP relies on surrogate measures such as hematologic recovery, normalization of serum lactate dehydrogenase (LDH) and resolution of clinical signs, it is plausible that some recurrences are actually a continuum of disease. Standardizing definitions for remission, exacerbation, and relapse are important for consistency of patient management and interpreting the medical literature. When TTP recurs, several adjuncts to therapeutic plasma exchange (TPE) have been used, including splenectomy, vincristine, and rituximab. Although it would seem intuitive that more severe disease would predict a greater likelihood of relapse, the degree of thrombocytopenia at presentation, the persistence of schistocytosis at discontinuation of TPE, the elevation of LDH, and the length of time to attain clinical remission are not reliable indicators of the clinical outcome of any individual TTP patient. Measurement of ADAMTS13 activity and its inhibitor offer new promise for prognostic and pathophysiologic significance; however, more extensive scientific investigation is needed.

KW - Adjunct therapy

KW - Prognostic factors

KW - Relapse

KW - Thrombotic thrombocytopenic purpura (TTP)

UR - http://www.scopus.com/inward/record.url?scp=30344433272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344433272&partnerID=8YFLogxK

U2 - 10.1055/s-2005-925476

DO - 10.1055/s-2005-925476

M3 - Review article

C2 - 16388421

AN - SCOPUS:30344433272

VL - 31

SP - 700

EP - 708

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 6

ER -